CA2421582A1 - Combinatorial fluorescence energy transfer tags and uses thereof - Google Patents
Combinatorial fluorescence energy transfer tags and uses thereof Download PDFInfo
- Publication number
- CA2421582A1 CA2421582A1 CA002421582A CA2421582A CA2421582A1 CA 2421582 A1 CA2421582 A1 CA 2421582A1 CA 002421582 A CA002421582 A CA 002421582A CA 2421582 A CA2421582 A CA 2421582A CA 2421582 A1 CA2421582 A1 CA 2421582A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- nucleic acid
- oligonucleotide
- dna
- matter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012546 transfer Methods 0.000 title claims abstract description 44
- 239000002062 molecular scaffold Substances 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims description 101
- 238000000034 method Methods 0.000 claims description 90
- 108091034117 Oligonucleotide Proteins 0.000 claims description 79
- 125000003729 nucleotide group Chemical group 0.000 claims description 77
- 102000039446 nucleic acids Human genes 0.000 claims description 62
- 108020004707 nucleic acids Proteins 0.000 claims description 62
- 150000007523 nucleic acids Chemical class 0.000 claims description 61
- 108020004414 DNA Proteins 0.000 claims description 60
- 239000000975 dye Substances 0.000 claims description 54
- 239000002773 nucleotide Substances 0.000 claims description 42
- 229910019142 PO4 Inorganic materials 0.000 claims description 33
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 29
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 29
- 239000010452 phosphate Substances 0.000 claims description 29
- 239000007850 fluorescent dye Substances 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 27
- 239000005546 dideoxynucleotide Substances 0.000 claims description 25
- 238000000295 emission spectrum Methods 0.000 claims description 20
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 16
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 16
- 230000005284 excitation Effects 0.000 claims description 16
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical group C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 claims description 15
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical group CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 14
- 230000005855 radiation Effects 0.000 claims description 13
- 230000000295 complement effect Effects 0.000 claims description 12
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims description 12
- 229960002685 biotin Drugs 0.000 claims description 11
- 239000011616 biotin Substances 0.000 claims description 11
- 102000012410 DNA Ligases Human genes 0.000 claims description 10
- 108010061982 DNA Ligases Proteins 0.000 claims description 10
- 238000006116 polymerization reaction Methods 0.000 claims description 9
- 108010090804 Streptavidin Proteins 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 239000002096 quantum dot Substances 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 238000009396 hybridization Methods 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 claims description 6
- 239000001226 triphosphate Substances 0.000 claims description 6
- 235000011178 triphosphate Nutrition 0.000 claims description 6
- HBROZNQEVUILML-UHFFFAOYSA-N salicylhydroxamic acid Chemical compound ONC(=O)C1=CC=CC=C1O HBROZNQEVUILML-UHFFFAOYSA-N 0.000 claims description 4
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 4
- XKKCQTLDIPIRQD-JGVFFNPUSA-N 1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 XKKCQTLDIPIRQD-JGVFFNPUSA-N 0.000 claims description 3
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 claims description 3
- 229920000388 Polyphosphate Polymers 0.000 claims description 3
- OTXOHOIOFJSIFX-POYBYMJQSA-N [[(2s,5r)-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)O)CC[C@@H]1N1C(=O)NC(=O)C=C1 OTXOHOIOFJSIFX-POYBYMJQSA-N 0.000 claims description 3
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 claims description 3
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 claims description 3
- 239000001205 polyphosphate Substances 0.000 claims description 3
- 235000011176 polyphosphates Nutrition 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 abstract description 26
- 239000013615 primer Substances 0.000 description 71
- 102000053602 DNA Human genes 0.000 description 56
- 239000000047 product Substances 0.000 description 39
- 230000035772 mutation Effects 0.000 description 28
- 235000021317 phosphate Nutrition 0.000 description 25
- 210000000349 chromosome Anatomy 0.000 description 24
- 238000013459 approach Methods 0.000 description 19
- 238000001514 detection method Methods 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 125000006850 spacer group Chemical group 0.000 description 17
- 239000000370 acceptor Substances 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000001962 electrophoresis Methods 0.000 description 12
- 238000011161 development Methods 0.000 description 10
- 238000001712 DNA sequencing Methods 0.000 description 9
- 201000000582 Retinoblastoma Diseases 0.000 description 9
- 238000010276 construction Methods 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 101150002130 Rb1 gene Proteins 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 208000036878 aneuploidy Diseases 0.000 description 7
- 231100001075 aneuploidy Toxicity 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000007834 ligase chain reaction Methods 0.000 description 5
- 150000008300 phosphoramidites Chemical class 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108091029845 Aminoallyl nucleotide Proteins 0.000 description 4
- 206010064571 Gene mutation Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- 238000001215 fluorescent labelling Methods 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- ZOADTRDGOSLUFJ-BYPYZUCNSA-N (2s)-1-azidopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1N=[N+]=[N-] ZOADTRDGOSLUFJ-BYPYZUCNSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002559 cytogenic effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000016507 interphase Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 238000003800 Staudinger reaction Methods 0.000 description 2
- 229910052771 Terbium Inorganic materials 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical class [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000010422 painting Methods 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 108060006184 phycobiliprotein Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 150000003147 proline derivatives Chemical class 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LFRDGHVRPSURMV-YFKPBYRVSA-N (4s)-4,5-dihydroxypentanal Chemical compound OC[C@@H](O)CCC=O LFRDGHVRPSURMV-YFKPBYRVSA-N 0.000 description 1
- KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- KBDWGFZSICOZSJ-UHFFFAOYSA-N 5-methyl-2,3-dihydro-1H-pyrimidin-4-one Chemical compound N1CNC=C(C1=O)C KBDWGFZSICOZSJ-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 0 CC(C1)*1NN Chemical compound CC(C1)*1NN 0.000 description 1
- 101710184216 Cardioactive peptide Proteins 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 208000025939 DNA Repair-Deficiency disease Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101900234631 Escherichia coli DNA polymerase I Proteins 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000000039 Heat Shock Transcription Factor Human genes 0.000 description 1
- 108050008339 Heat Shock Transcription Factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000033321 ICF syndrome Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- -1 NHS ester Chemical class 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 208000033787 Rare developmental defect during embryogenesis Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 101900178114 Thermoplasma acidophilum Inorganic pyrophosphatase Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000022734 developmental defect during embryogenesis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 208000004731 long QT syndrome Diseases 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 208000035853 malformation syndrome Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000011155 quantitative monitoring Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Mathematical Physics (AREA)
- Theoretical Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/658,077 US6627748B1 (en) | 2000-09-11 | 2000-09-11 | Combinatorial fluorescence energy transfer tags and their applications for multiplex genetic analyses |
| US09/658,077 | 2000-09-11 | ||
| US30915601P | 2001-07-31 | 2001-07-31 | |
| US60/309,156 | 2001-07-31 | ||
| PCT/US2001/028967 WO2002022883A1 (en) | 2000-09-11 | 2001-09-11 | Combinatorial fluorescence energy transfer tags and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2421582A1 true CA2421582A1 (en) | 2002-03-21 |
Family
ID=26976642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002421582A Abandoned CA2421582A1 (en) | 2000-09-11 | 2001-09-11 | Combinatorial fluorescence energy transfer tags and uses thereof |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1322785A4 (de) |
| JP (1) | JP2004508838A (de) |
| AU (1) | AU8911101A (de) |
| CA (1) | CA2421582A1 (de) |
| WO (1) | WO2002022883A1 (de) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6627748B1 (en) | 2000-09-11 | 2003-09-30 | The Trustees Of Columbia University In The City Of New York | Combinatorial fluorescence energy transfer tags and their applications for multiplex genetic analyses |
| DE60127162T2 (de) | 2000-10-06 | 2008-04-24 | The Trustees Of Columbia University In The City Of New York | Massives Parallelverfahren zur Dekodierung von DNA und RNA |
| US9708358B2 (en) | 2000-10-06 | 2017-07-18 | The Trustees Of Columbia University In The City Of New York | Massive parallel method for decoding DNA and RNA |
| US6942853B2 (en) * | 2001-01-09 | 2005-09-13 | Queen Mary And Westfield College | Latent fusion protein |
| US7057026B2 (en) | 2001-12-04 | 2006-06-06 | Solexa Limited | Labelled nucleotides |
| GB0129012D0 (en) | 2001-12-04 | 2002-01-23 | Solexa Ltd | Labelled nucleotides |
| US7074597B2 (en) | 2002-07-12 | 2006-07-11 | The Trustees Of Columbia University In The City Of New York | Multiplex genotyping using solid phase capturable dideoxynucleotides and mass spectrometry |
| US7414116B2 (en) | 2002-08-23 | 2008-08-19 | Illumina Cambridge Limited | Labelled nucleotides |
| US11008359B2 (en) | 2002-08-23 | 2021-05-18 | Illumina Cambridge Limited | Labelled nucleotides |
| DK3363809T3 (da) | 2002-08-23 | 2020-05-04 | Illumina Cambridge Ltd | Modificerede nukleotider til polynukleotidsekvensering |
| EP2436778A3 (de) | 2004-03-03 | 2012-07-11 | The Trustees of Columbia University in the City of New York | Photospaltbare fluoreszierende Nukleotide zur DNA-Sequenzierung auf einem durch ortsspezifische Kopplungschemie konstruierten Chip |
| US9040305B2 (en) | 2004-09-28 | 2015-05-26 | Singulex, Inc. | Method of analysis for determining a specific protein in blood samples using fluorescence spectrometry |
| US8685711B2 (en) | 2004-09-28 | 2014-04-01 | Singulex, Inc. | Methods and compositions for highly sensitive detection of molecules |
| US7060955B1 (en) * | 2005-01-31 | 2006-06-13 | Chemimage Corporation | Apparatus and method for defining illumination parameters of a sample |
| US9169510B2 (en) | 2005-06-21 | 2015-10-27 | The Trustees Of Columbia University In The City Of New York | Pyrosequencing methods and related compositions |
| GB2446084B (en) | 2005-10-31 | 2011-03-02 | Univ Columbia | Synthesis of four color 3-o-allyl modified photocleavable fluorescent nucleotides and related methods |
| US8796432B2 (en) | 2005-10-31 | 2014-08-05 | The Trustees Of Columbia University In The City Of New York | Chemically cleavable 3'-o-allyl-DNTP-allyl-fluorophore fluorescent nucleotide analogues and related methods |
| JP5308328B2 (ja) * | 2006-04-04 | 2013-10-09 | シングレックス，インコーポレイテッド | トロポニンの分析のための高感度のシステムおよび方法 |
| EP1860197A1 (de) * | 2006-05-24 | 2007-11-28 | Humboldt-Universität zu Berlin | Verfahren zum Nachweis von einer Zielnukleinsäure mit Verwendung von template katalysierter Reaktion |
| CN101495656B (zh) | 2006-06-07 | 2017-02-08 | 纽约哥伦比亚大学理事会 | 采用带修饰的核苷酸通过纳米通道进行dna序列测定 |
| EP2071927A2 (de) | 2006-09-28 | 2009-06-24 | Illumina, Inc. | Zusammensetzungen und verfahren zur nukleotidsequenzierung |
| GB2457402B (en) | 2006-12-01 | 2011-10-19 | Univ Columbia | Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators |
| GB0700640D0 (en) * | 2007-01-12 | 2007-02-21 | Iti Scotland Ltd | Detecting analytes |
| DK2725107T3 (da) | 2007-10-19 | 2019-01-02 | Univ Columbia | DNA-sekventering med ikke-fluorescerende nukleotidreversible terminatorer og ddNTP'er modificeret med spaltbart mærke og nukleinsyre omfattende inosin med reversible terminatorer |
| WO2009051807A1 (en) | 2007-10-19 | 2009-04-23 | The Trustees Of Columbia University In The City Of New York | Design and synthesis of cleavable fluorescent nucleotides as reversible terminators for dna sequencing by synthesis |
| US7914734B2 (en) | 2007-12-19 | 2011-03-29 | Singulex, Inc. | Scanning analyzer for single molecule detection and methods of use |
| US9678055B2 (en) | 2010-02-08 | 2017-06-13 | Genia Technologies, Inc. | Methods for forming a nanopore in a lipid bilayer |
| US8324914B2 (en) | 2010-02-08 | 2012-12-04 | Genia Technologies, Inc. | Systems and methods for characterizing a molecule |
| US9605307B2 (en) | 2010-02-08 | 2017-03-28 | Genia Technologies, Inc. | Systems and methods for forming a nanopore in a lipid bilayer |
| WO2012083249A2 (en) | 2010-12-17 | 2012-06-21 | The Trustees Of Columbia University In The City Of New York | Dna sequencing by synthesis using modified nucleotides and nanopore detection |
| US9121059B2 (en) | 2010-12-22 | 2015-09-01 | Genia Technologies, Inc. | Nanopore-based single molecule characterization |
| US9581563B2 (en) | 2011-01-24 | 2017-02-28 | Genia Technologies, Inc. | System for communicating information from an array of sensors |
| US9110478B2 (en) | 2011-01-27 | 2015-08-18 | Genia Technologies, Inc. | Temperature regulation of measurement arrays |
| US9624539B2 (en) | 2011-05-23 | 2017-04-18 | The Trustees Of Columbia University In The City Of New York | DNA sequencing by synthesis using Raman and infrared spectroscopy detection |
| US8986629B2 (en) | 2012-02-27 | 2015-03-24 | Genia Technologies, Inc. | Sensor circuit for controlling, detecting, and measuring a molecular complex |
| CN107082792A (zh) | 2012-04-09 | 2017-08-22 | 纽约哥伦比亚大学理事会 | 纳米孔的制备方法和其用途 |
| CN104350162A (zh) | 2012-06-15 | 2015-02-11 | 吉尼亚科技公司 | 芯片设置和高精确度核酸测序 |
| US20150119259A1 (en) | 2012-06-20 | 2015-04-30 | Jingyue Ju | Nucleic acid sequencing by nanopore detection of tag molecules |
| US9605309B2 (en) | 2012-11-09 | 2017-03-28 | Genia Technologies, Inc. | Nucleic acid sequencing using tags |
| US9759711B2 (en) | 2013-02-05 | 2017-09-12 | Genia Technologies, Inc. | Nanopore arrays |
| AU2014248511B2 (en) * | 2013-03-12 | 2018-05-10 | Myriad Women’s Health, Inc. | Systems and methods for prenatal genetic analysis |
| CN105102627B (zh) | 2013-03-15 | 2018-10-19 | 纽约哥伦比亚大学理事会 | 用于检测样品中多种预定化合物的方法 |
| CN105377869B (zh) | 2013-03-15 | 2018-07-10 | 伊鲁米纳剑桥有限公司 | 修饰的核苷或核苷酸 |
| US10648026B2 (en) | 2013-03-15 | 2020-05-12 | The Trustees Of Columbia University In The City Of New York | Raman cluster tagged molecules for biological imaging |
| JP6190534B2 (ja) | 2013-08-22 | 2017-08-30 | ソニー株式会社 | 水溶性蛍光染料又は有色染料及びその使用方法 |
| US9551697B2 (en) | 2013-10-17 | 2017-01-24 | Genia Technologies, Inc. | Non-faradaic, capacitively coupled measurement in a nanopore cell array |
| US9322062B2 (en) | 2013-10-23 | 2016-04-26 | Genia Technologies, Inc. | Process for biosensor well formation |
| CN105723222B (zh) | 2013-10-23 | 2019-01-22 | 吉尼亚科技公司 | 使用纳米孔的高速分子感测 |
| AU2015236392A1 (en) | 2014-03-24 | 2016-10-20 | Genia Technologies, Inc. | Chemical methods for producing tagged nucleotides |
| EP3262022A4 (de) | 2015-02-26 | 2018-08-15 | Sony Corporation | Phenylethynylnaphthalenfarbstoffe und verfahren zu deren verwendung |
| EP3262055A4 (de) | 2015-02-26 | 2018-09-05 | Sony Corporation | Wasserlösliche fluoreszente oder farbige farbstoffe mit konjugierungsgruppen |
| WO2016144973A1 (en) | 2015-03-09 | 2016-09-15 | The Trustees Of Columbia University In The City Of New York | Pore-forming protein conjugate compositions and methods |
| US10865310B2 (en) | 2015-05-11 | 2020-12-15 | Sony Corporation Of America | Ultra bright dimeric or polymeric dyes |
| EP3356381A4 (de) | 2015-09-28 | 2019-06-12 | The Trustees of Columbia University in the City of New York | Design und synthese von auf neuartigem disulfidverbinder basierenden nukleotiden als reversible terminatoren zur dna-sequenzierung durch synthese |
| US11434377B2 (en) | 2016-04-01 | 2022-09-06 | Sony Corporation | Ultra bright dimeric or polymeric dyes with rigid spacing groups |
| AU2017240154B2 (en) | 2016-04-01 | 2021-08-12 | Sony Group Corporation | Ultra bright dimeric or polymeric dyes |
| US9851359B2 (en) | 2016-04-06 | 2017-12-26 | Sony Corporation Of America | Ultra bright dimeric or polymeric dyes with spacing linker groups |
| US11390754B2 (en) | 2016-05-10 | 2022-07-19 | Sony Corporation | Compositions comprising a polymeric dye and a cyclodextrin and uses thereof |
| WO2017196954A1 (en) | 2016-05-10 | 2017-11-16 | Sony Corporation | Ultra bright polymeric dyes with peptide backbones |
| JP7071286B2 (ja) | 2016-05-11 | 2022-05-18 | ソニーグループ株式会社 | 超明色ダイマーまたはポリマー染料 |
| US11266673B2 (en) | 2016-05-23 | 2022-03-08 | The Trustees Of Columbia University In The City Of New York | Nucleotide derivatives and methods of use thereof |
| JP7068191B2 (ja) | 2016-06-06 | 2022-05-16 | ソニーグループ株式会社 | 蛍光または有色レポーター基を含むイオン性ポリマー |
| US12018159B2 (en) | 2016-07-29 | 2024-06-25 | Sony Group Corporation | Ultra bright dimeric or polymeric dyes and methods for preparation of the same |
| WO2018165207A1 (en) | 2017-03-06 | 2018-09-13 | Singular Genomic Systems, Inc. | Nucleic acid sequencing-by-synthesis (sbs) methods that combine sbs cycle steps |
| EP3600339A4 (de) | 2017-03-28 | 2021-05-19 | The Trustees of Columbia University in the City of New York | 3'-o-modifizierte nukleotidanaloga mit verschiedenen spaltbaren linkern zur befestigung von fluoreszenzmarkierungen an der base zur dna-sequenzierung durch synthese |
| EP3438649B1 (de) * | 2017-07-31 | 2020-03-11 | Vestel Elektronik Sanayi ve Ticaret A.S. | Identifizierungs-tag und verfahren zum identifizieren eines objekts |
| US20210032277A1 (en) | 2017-10-05 | 2021-02-04 | Sony Corporation | Programmable polymeric drugs |
| KR20200083605A (ko) | 2017-11-16 | 2020-07-08 | 소니 주식회사 | 프로그램가능한 중합체성 약물 |
| US11874280B2 (en) | 2018-03-19 | 2024-01-16 | Sony Group Corporation | Use of divalent metals for enhancement of fluorescent signals |
| EP3768689A1 (de) | 2018-03-21 | 2021-01-27 | Sony Corporation | Polymere tandemfarbstoffe mit linkergruppen |
| US12006438B2 (en) | 2018-06-27 | 2024-06-11 | Sony Group Corporation | Polymeric dyes with linker groups comprising deoxyribose |
| US10738072B1 (en) | 2018-10-25 | 2020-08-11 | Singular Genomics Systems, Inc. | Nucleotide analogues |
| JP2022516684A (ja) | 2019-01-08 | 2022-03-01 | シンギュラー・ゲノミクス・システムズ・インコーポレイテッド | ヌクレオチドの開裂可能なリンカーおよびその使用 |
| CN113383043A (zh) | 2019-09-26 | 2021-09-10 | 索尼集团公司 | 具有连接体基团的聚合物串联染料 |
| JPWO2023032995A1 (de) | 2021-08-31 | 2023-03-09 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4824775A (en) * | 1985-01-03 | 1989-04-25 | Molecular Diagnostics, Inc. | Cells labeled with multiple Fluorophores bound to a nucleic acid carrier |
| US5654419A (en) * | 1994-02-01 | 1997-08-05 | The Regents Of The University Of California | Fluorescent labels and their use in separations |
| JP3439221B2 (ja) * | 1995-12-18 | 2003-08-25 | ワシントン ユニヴァーシティ | 蛍光共鳴エネルギー移動を利用する核酸分析方法 |
| US5853992A (en) * | 1996-10-04 | 1998-12-29 | The Regents Of The University Of California | Cyanine dyes with high-absorbance cross section as donor chromophores in energy transfer labels |
| US5804386A (en) * | 1997-01-15 | 1998-09-08 | Incyte Pharmaceuticals, Inc. | Sets of labeled energy transfer fluorescent primers and their use in multi component analysis |
| US5834203A (en) * | 1997-08-25 | 1998-11-10 | Applied Spectral Imaging | Method for classification of pixels into groups according to their spectra using a plurality of wide band filters and hardwire therefore |
| ATE461451T1 (de) * | 1999-10-08 | 2010-04-15 | Robert C Leif | Markerkomplexe aus konjugierten polymeren |
-
2001
- 2001-09-11 JP JP2002527323A patent/JP2004508838A/ja not_active Withdrawn
- 2001-09-11 AU AU8911101A patent/AU8911101A/xx active Pending
- 2001-09-11 CA CA002421582A patent/CA2421582A1/en not_active Abandoned
- 2001-09-11 EP EP01968905A patent/EP1322785A4/de not_active Withdrawn
- 2001-09-11 WO PCT/US2001/028967 patent/WO2002022883A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002022883A1 (en) | 2002-03-21 |
| EP1322785A1 (de) | 2003-07-02 |
| AU8911101A (en) | 2002-03-26 |
| JP2004508838A (ja) | 2004-03-25 |
| EP1322785A4 (de) | 2005-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060057565A1 (en) | Combinatorial fluorescence energy transfer tags and uses thereof | |
| US6627748B1 (en) | Combinatorial fluorescence energy transfer tags and their applications for multiplex genetic analyses | |
| CA2421582A1 (en) | Combinatorial fluorescence energy transfer tags and uses thereof | |
| US6258539B1 (en) | Restriction enzyme mediated adapter | |
| US9404155B2 (en) | Alternative nucleic acid sequencing methods | |
| Tong et al. | Combinatorial fluorescence energy transfer tags for multiplex biological assays | |
| US5824481A (en) | DNA analyzing method | |
| US7371520B2 (en) | Methods and apparati using single polymer analysis | |
| US5427911A (en) | Coupled amplification and sequencing of DNA | |
| US10072287B2 (en) | Methods of targeted sequencing | |
| US20030235854A1 (en) | Methods for analyzing a nucleic acid | |
| US20050123944A1 (en) | Methods and compositions related to the use of sequence-specific endonucleases for analyzing nucleic acids under non-cleaving conditions | |
| JPH03502041A (ja) | Ｄｎａおよびｒｎａの迅速塩基配列決定方法 | |
| JPH08211050A (ja) | 特定核酸配列の検出方法 | |
| JP2004507230A (ja) | ポリヌクレオチド配列アッセイ | |
| JPH07505529A (ja) | プローブ構成物および方法 | |
| EP2956550B1 (de) | Verbesserte sondenanbindung | |
| WO2000047766A1 (en) | Method for detecting variant nucleotides using arms multiplex amplification | |
| JP4297966B2 (ja) | 標識ヌクレオチドを利用することによる核酸の新規測定方法 | |
| CN109689883A (zh) | 用于连接细胞组成物和基质的方法 | |
| Tong et al. | Combinatorial fluorescence energy transfer tags: New molecular tools for genomics applications | |
| JP4276897B2 (ja) | 標識ヌクレオチドを利用することによる核酸の新規測定方法 | |
| CN101519698B (zh) | 一种利用序列标签定量测定核酸的方法 | |
| Lopez-Crapez et al. | Detection of K-ras Mutations by a Microelectronic DNA Chip | |
| Du et al. | Minisequencing on functionalised self-assembled monolayer as a simple approach for single nucleotide polymorphism analysis of cattle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |